Eye Catching Stocks : BP p.l.c. (NYSE:BP), Intel (NASDAQ:INTC), Bristol-Myers Squibb (NYSE:BMY), BioScrip Inc. (NASDAQ:BIOS), Willis Group Holdings Public Company (NYSE:WSH),

BP plc (NYSE:BP)‘s stock had its “neutral” rating reissued by analysts at Oddo & Cie in a research report issued to clients and investors on Friday. They currently have a GBX 510 ($8.29) price target on the stock. Oddo & Cie’s price objective suggests a potential upside of 8.48% from the stock’s previous close. BP p.l.c. (NYSE:BP)’s stock on 15 September traded at beginning with a price of $45.59 and when day-trade ended the stock finally decreased -0.11% to end at $45.89. BP p.l.c. (NYSE:BP)’s showed weekly performance of 1.24%.

Intel Corporation (NASDAQ:INTC) is aiming for a future where cables are not necessary for computers as the company recently highlighted WiGig, a fast Wi-Fi standard, and wireless charging at the Intel Developer Forum 2014 (IDF14). Intel Corporation (NASDAQ:INTC) on Monday closed at $34.54. Stock institutional ownership is 66.00% while insider ownership includes 0.07%. Intel Corporation (NASDAQ:INTC) distance from 50-day simple moving average (SMA50) is 2.58%.

Merck & Co., Inc. (MRK) won the US Food and Drug Administration’s (FDA) Accelerated Approval for its breakthrough cancer therapy, Keytruda. It beat Bristol-Myers Squibb Company (NYSE:BMY) by becoming the first company first to get approval for a PD-1 inhibitor drug in the US. Keytruda has been approved for the treatment of advanced melanoma in patients who have failed treatments with Bristol-Myers’ Yervoy and other drugs. The PD-1 inhibitor drug belongs to a new generation of drugs which boost the patient’s immune system to fight cancerous cells. Merck expects to launch Keytruda within one week. Bristol-Myers Squibb Company (NYSE:BMY)’s shares on Monday traded in the range of 49.75 – 50.37and ended up on $49.95. Bristol-Myers Squibb Company (NYSE:BMY) distance from 200-day simple moving average (SMA200) is -0.92%. BMY’s sales growth for past 5 years was -1.50% and its EPS growth for past 5 years was -3.60%.

BioScrip Inc. (NASDAQ:BIOS) has been divesting assets for a year now, but the health services company could find itself a target for both large strategic and financial players because of the strength of its in-home medicine business, according to industry sources. BioScrip Inc. (NASDAQ:BIOS)’s stock on 15 September decreased -2.22% to the closing price of $7.93. Its fifty two weeks range is $5.61 – 11.95. The total market capitalization recorded $544.1M. BioScrip Inc. (NASDAQ:BIOS) monthly performance is -0.63%.

Keefe, Bruyette & Woods upgraded shares of Willis Group Holdings PLC (NYSE:WSH) from a market perform rating to an outperform rating in a report issued on Tuesday. They currently have $49.00 target price on the stock, up from their previous target price of $46.00. Willis Group Holdings Public Limited Company (NYSE:WSH) on Monday closed at $42.55. Stock institutional ownership is 97.30% while insider ownership includes 0.20%. Willis Group Holdings Public Limited Company (NYSE:WSH) distance from 50-day simple moving average (SMA50) is 1.58%.